AI-Crafted mRNA vaccine takes on advanced cancers in first human test
NCT ID NCT07560943
First seen May 03, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This early-phase study tests a new mRNA vaccine, designed by artificial intelligence, in 9 people with advanced solid tumors that have not responded to standard treatments. The vaccine is injected directly into tumors to teach the immune system to attack cancer cells. The main goal is to check safety, but researchers will also look for any signs of tumor shrinkage or control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The West China Hospital
RECRUITINGChengdu, Sichuan, 646000, China
-
West China Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.